Milnacipran Impurity 13, with the CAS number 710339-49-4, is a chemical compound that is recognized as an impurity associated with the synthesis of milnacipran, a medication primarily used to treat fibromyalgia and major depressive disorder. While specific characteristics such as molecular weight, structure, and solubility may vary, impurities like this one are typically characterized by their potential to affect the purity and efficacy of the primary compound. Impurities can arise during the manufacturing process and may influence the pharmacological properties of the drug. In general, impurities are assessed for their stability, reactivity, and potential toxicity. Regulatory agencies often require detailed characterization of such impurities to ensure safety and compliance with pharmaceutical standards. Understanding the properties of Milnacipran Impurity 13 is crucial for quality control in drug formulation and development, as well as for ensuring that the final pharmaceutical product meets the necessary safety and efficacy criteria.

Milnacipran Impurity 13

710339-49-4: Milnacipran Impurity 13, with the CAS number 710339-49-4, is a chemical compound that is recognized as an impurity associated with the synthesis of milnacipran, a medication primarily used to treat fibromyalgia and major depressive disorder. While specific characteristics such as molecular weight, structure, and solubility may vary, impurities like this one are typically characterized by their potential to affect the purity and efficacy of the primary compound. Impurities can arise during the manufacturing process and may influence the pharmacological properties of the drug. In general, impurities are assessed for their stability, reactivity, and potential toxicity. Regulatory agencies often require detailed characterization of such impurities to ensure safety and compliance with pharmaceutical standards. Understanding the properties of Milnacipran Impurity 13 is crucial for quality control in drug formulation and development, as well as for ensuring that the final pharmaceutical product meets the necessary safety and efficacy criteria.

CAS 710339-49-4

Milnacipran Impurity 13

Milnacipran Impurity 13

Ref: 4Z-M-4126